GC Green Cross 'Vimax Series' (Photo by GC Green Cross)

GC Green Cross 'Vimax Series' (Photo by GC Green Cross)

View original image

[Asia Economy Reporter Chunhee Lee] GCGreen Cross's high-dose vitamin B complex 'B-Max' has surpassed 50 billion KRW in annual sales, continuing its growth trend.


GC Green Cross announced on the 11th that B-Max's sales exceeded 50 billion KRW last year. Having achieved 10 billion KRW in sales in 2017, B-Max has since maintained a steep growth rate of 50% annually.


The company explained that in addition to B-Max's excellent product quality, the customized lineup of seven B-Max series tailored by generation and gender drove this growth. Among them, the flagship product leading the growth is 'B-Max Meta.' B-Max Meta contains highly bioavailable active vitamin B groups along with about ten essential vitamins and various minerals necessary for modern people, making it effective for recovering from chronic fatigue and improving physical decline. Furthermore, 'B-Max Meta-V,' released last year, increased the content of 'Bisbentiamine,' which crosses the blood-brain barrier, enhancing the activation effect of brain energy metabolism.


Additionally, the lineup includes ▲ 'B-Max Active' and 'B-Max Gold,' which evenly contain active vitamins and minerals ▲ the women's product 'B-Max BB,' fortified with antioxidants ▲ 'B-Max Ever,' containing herbal ingredients that help restore vitality in middle-aged and older adults ▲ and 'B-Max MG Active,' which contains a high dose of magnesium effective for muscle cramps and blood circulation, allowing consumers to choose products according to their needs.



Lee Wonjae, brand manager of GC Green Cross, said, “Due to the prolonged COVID-19 pandemic, B-Max, with its excellent product quality, has received great love from consumers,” and added, “We will continue to strengthen quality and grow as the representative vitamin B product.”


This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing